Preliminary Collaboration AgreementPreliminary Collaboration Agreement • May 6th, 2021 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances)
This Preliminary Collaboration Agreement (this “Preliminary Collaboration Agreement” or “PCA”) is entered into as of February 14, 2021 (the “PCA Execution Date”), by and between Glaxo Wellcome UK Limited, (“GSK”) and Vir Biotechnology, Inc. (“VIR”). VIR and GSK may be referred to individually as a “Party” and collectively as the “Parties.” Reference is made to that certain Definitive Collaboration Agreement between GSK and VIR dated June 9, 2020 (the “Existing Collaboration Agreement”). This PCA sets forth the key terms upon which the Parties would expand the collaboration to include (a) an antibody program directed towards influenza, (b) functional genomics approaches to Respiratory Viral Diseases (as defined below), and (c) antibody programs directed towards additional pathogens, each, as further described below (collectively, the “Collaboration”). It is anticipated that following the PCA Execution Date, the Parties will enter into a definitive agreement to include more detailed term
Preliminary Collaboration AgreementPreliminary Collaboration Agreement • February 2nd, 2021 • Delaware
This Preliminary Collaboration Agreement (“Preliminary Collaboration Agreement”) is entered into as of April 5, 2020 (the “Execution Date”), by and between GlaxoSmithKline Intellectual Property Development Limited, a limited liability company incorporated under the laws of England having an office at 980 Great West Road, Brentford, Middlesex, TW8 9GS, UK, and GlaxoSmithKline Biologicals SA, a limited liability company incorporated under the laws of Belgium having its registered place of business at rue de l’Institut 89, 1330 Rixensart, Belgium, registered with the Legal Entity Register (RPM Nivelles) under number 0440.72.918 (together, “GSK”), and Vir Biotechnology, Inc., a Delaware corporation having an office at 499 Illinois Street, Suite 500, San Francisco, CA 94158 (“Vir”) (each GSK and Vir, a “Party” and together, the “Parties”). The capitalized terms used herein and not otherwise defined have the meanings given to them in the Stock Purchase Agreement.
Preliminary Collaboration AgreementPreliminary Collaboration Agreement • June 23rd, 2020 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances) • Delaware
This Preliminary Collaboration Agreement (“Preliminary Collaboration Agreement”) is entered into as of April 5, 2020 (the “Execution Date”), by and between GlaxoSmithKline Intellectual Property Development Limited, a limited liability company incorporated under the laws of England having an office at 980 Great West Road, Brentford, Middlesex, TW8 9GS, UK, and GlaxoSmithKline Biologicals SA, a limited liability company incorporated under the laws of Belgium having its registered place of business at rue de l’Institut 89, 1330 Rixensart, Belgium, registered with the Legal Entity Register (RPM Nivelles) under number 0440.72.918 (together, “GSK”), and Vir Biotechnology, Inc., a Delaware corporation having an office at 499 Illinois Street, Suite 500, San Francisco, CA 94158 (“Vir”) (each GSK and Vir, a “Party” and together, the “Parties”). The capitalized terms used herein and not otherwise defined have the meanings given to them in the Stock Purchase Agreement.
